Catherine Hanley

Catherine Hanley

Vice President, Marketing & Customer Experience

Recent posts by Catherine Hanley

Lyophilized products are on the rise: Here's what you need to know

By Catherine Hanley on Jul 5, 2021 10:48:00 AM

There has been a steady increase in demand for lyophilized products in recent years. Due in large part to biologic drug innovation and technological advancement in the lyophilization process as well as ease of access to outsourcing partners who specialize in the formulation development and manufacturing of lyophilized biological products. 

In this article, Emergent experts discuss the factors that are driving the demand of lyophilized products and what to consider when selecting a CDMO partner to support your drug manufacturing needs. 

Download Article

Topics: Fill/Finish

Rockville, MD Expansion Progress

By Catherine Hanley on May 12, 2021 3:56:00 PM

Our drug product manufacturing facility in Rockville, Maryland is undergoing an expansion that will soon house a state-of-the-art high speed fill/finish line with fully integrated isolator technology and an automated inspection, labeling, and packaging line. Take a look at the time lapse video of our progress so far!

Rockville CDMO Expansion
Topics: Drug Product Fill/Finish
1 min read


By Catherine Hanley on Apr 14, 2021 11:47:00 AM

Watch our latest webinar on the topic of aseptic fill/finish and isolator-based technology for pre-sterilized syringes, cartridges, and vials.

Topics: webinar Drug Product Fill/Finish
1 min read

Genetic Vaccine Platforms Demonstrate Their Potential

By Catherine Hanley on Mar 12, 2021 9:00:00 AM

In a recent Pharmaceutical Technology article, Emergent experts provide their insights on selection of technologies for vaccine development. 

Read the full article here. 

Topics: editorials

Emergent Enters Into a New CDMO Agreement with Providence Therapeutics to Provide Fill/Finish Drug Product Manufacturing

By Catherine Hanley on Feb 12, 2021 2:00:00 PM

Emergent has entered into a new CDMO agreement with Providence Therapeutics to provide fill/finish drug product manufacturing services for their investigational mRNA vaccine candidate (PTX-COVID19-B) at its facility in Winnipeg, Manitoba, Canada. This is Emergent's 8th COVID-19 CDMO collaboration, and first outside of the U.S. in Canada.

Topics: COVID-19 news
6 min read

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™

By Catherine Hanley on Jan 25, 2021 9:23:46 AM

GAITHERSBURG, MD. and BURLINGAME, CA. – Jan. 25, 2021  Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a contract development and manufacturing (CDMO) services agreement to accelerate the drug product manufacturing of lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune hyper-response called “cytokine storm.” Emergent will provide access to manufacturing capacity reserved for and provided by the U.S. government under Humanigen’s Cooperative Research and Development Agreement (CRADA) with the Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services. Lenzilumab is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for emergency use authorization (EUA) in the first quarter of 2021.

Topics: COVID-19 news

Emergent CDMO Virtual Booth

By Catherine Hanley on Jan 19, 2021 9:35:34 AM

Introducing Emergent’s new interactive CDMO booth display! Take a tour of our virtual booth to browse videos, download brochures and connect with our team to explore how we can support your next clinical or commercial project. 

Discover More

Topics: events

BioPharm Intl Regulatory Sourcebook: GMPs Guide COVID-19 Vaccine Manufacturing

By Catherine Hanley on Dec 1, 2020 11:27:00 AM

Excerpt taken from BioPharm International October 2020 Regulatory Sourcebook article titled: GMPs Guide COVID-19 Vaccine Manufacturing.

“The FDA Guidance highlights the pertinent CGMP [current good manufacturing practice] considerations for all vaccine manufacturing and serves as a reminder of statutory GMP expectations for COVID-19 vaccines specifically,” says Karolyn Gale, senior director, regulatory affairs, Emergent BioSolutions."

View the full article here.

Topics: editorials
1 min read

Factoring Stability in the Biologic Drug Mix

By Catherine Hanley on Nov 30, 2020 9:00:00 AM

Jee Look, senior director of drug product development for Emergent BioSolutions recently contributed to an article in Pharmaceutical Technology titled, "Factoring Stability in the Biological Drug Mix."

Stability issues can also occur at any stage of a vaccine’s development lifecycle, according to Jee Look, senior director of drug product development for Emergent BioSolutions’ contract development and manufacturing organization (CDMO) business. “In some cases, instability that occurs during upstream/downstream processing can be mitigated during final drug product manufacturing, but it is important to identify and understand the mechanisms of instability early in the pre-formulation stage as instability in the final drug product would have the largest impact on patient safety and overall production efficiency and would be more costly to fix,” he says.

Topics: editorials

Gene therapy solution: The value of a CDMO as your end-to-end partner

By Catherine Hanley on Oct 31, 2020 9:00:00 AM

With ongoing advances in science and technology, the cell and gene therapy pipeline has grown especially robust over the past few years. At present, Clinical shows more than 4,500 active gene therapy trials globally. In the United States, McKinsey experts expect to see 10 to 20 cell and gene therapy approvals per year over the next five years. 

This article discusses the important factors to consider when selecting an outsourcing partner for your advanced therapies. 

Download Article

Topics: advanced therapies